Biolinq Inc. has raised $10 million in a series A round to bring its pain-free blood glucose sensor to clinical trials. The financing was led by M Ventures, in collaboration with Hikma Ventures. Grey Sky Venture Partners, Three Leaf Ventures, Lifesci Venture Partners and a group of high-net-worth individuals specialized in the diabetes field also contributed to the round.